Danish Biotech Targeting Ion Channels Completes Private Placement

The biotech company Saniona has announced the issue of new shares to Swedish and international investors, raising a total of €3.6M.

Saniona, a Danish biotech listed on the Nasdaq First North Premier, just completed a private placement that raised €3.6M (SEK 35M) before issue costs. The funds are intended to provide the company with more flexibility to execute its business plan, which includes listing in the Nasdaq Stockholm this year.

Based in Copenhagen, the company develops small molecules that target ion channels. Its pipeline includes a wide range of conditions, such as obesity, type 2 diabetes, cocaine addiction, Parkinson’s, and schizophrenia, the latter being researched in collaboration with Boehringer Ingelheim.

Cover image via TJmedia /Shutterstock


Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.